Showing 1 - 10 of 10
Persistent link: https://www.econbiz.de/10010391799
Persistent link: https://www.econbiz.de/10012182271
Persistent link: https://www.econbiz.de/10011660496
Persistent link: https://www.econbiz.de/10001647271
Persistent link: https://www.econbiz.de/10000988889
Brand and generic drug manufacturers frequently settle patent litigation on terms that include a payment to the generic manufacturer along with a specified date at which the generic would enter the market. The Federal Trade Commission contends that these agreements extend the brand's market...
Persistent link: https://www.econbiz.de/10012458375
Persistent link: https://www.econbiz.de/10010528915
The Supreme Court recently held that in reverse-payment settlements of drug patent disputes, anticompetitive effects can be inferred if the reverse payment exceeds the patent holder's anticipated litigation costs, absent some offsetting justification. Application of this standard is problematic...
Persistent link: https://www.econbiz.de/10013004927
Brand and generic drug manufacturers frequently settle patent litigation on terms that include a payment to the generic manufacturer along with a specified date at which the generic would enter the market. The Federal Trade Commission contends that these agreements extend the brand's market...
Persistent link: https://www.econbiz.de/10013050310
This paper investigates the effects of stock market wealth on consumer spending. Traditional macroeconometric models estimate that a dollar's increase in stock market wealth boosts consumer spending by 3-7 cents per year. With the substantial 1990s rise in stock prices, the nature and magnitude...
Persistent link: https://www.econbiz.de/10014057423